Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTX301 in Advanced Solid Tumors
NCT05684965Phase 2Recruiting
- Sponsor
- Xilio Therapeutics
- Start
- May 2023
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efarindodekin alfa in solid tumor, head and neck squamous cell carcinoma (HNSCC), melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, sponsored by Xilio Therapeutics. Started May 2023; status: recruiting.
02
Drugs
efarindodekin alfa
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)melanomanon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT05684965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684965.